Press release

Siemens Healthineers with strong second-quarter performance despite COVID-19 pandemic

Siemens Healthineers AG today announced its results for the second quarter of fiscal year 2020 that ended March 31, 2020.

Q2 Fiscal Year 2020

  • Comparable revenue growth of 3.3% – negative COVID-19 impact of about 4 percentage points
  • Strong revenue performance in Imaging with 5.8% comparable growth and Advanced Therapies with 5.7% increase
  • Equipment book-to-bill with 0.94 only slightly below 1
  • Revenue decline by comp. 2.2% in Diagnostics in light of a declining number of patients due to the crisis burdens profitability
  • Adjusted EBIT margin at 17.9%, +10 bps year on year and clear improvement from Q1
  • Adjusted basic earnings per share rise 11% to €0.45
  • Q2 free cash flow resilient but below Q1 due to crisis-related inventory build-up
  • Outlook for FY 2020 no longer valid, Q3 expected to be trough

Bernd Montag, CEO of Siemens Healthineers AG:
"We stand shoulder to shoulder with our customers as a strong partner during the global COVID-19 pandemic. With our globally leading products and solutions, we are delivering support wherever we can. Overall, our business has performed well in the second quarter despite the pandemic and growing economic turbulence around the globe. We have increased our profitability from the first quarter, and thereby kept the promise we made. Currently, there are no reliable forecasts for the duration or intensity of the COVID-19 pandemic. Consequently, from today’s point of view, it is also not possible to make assumptions related to business development with certainty. Nevertheless, the fundamental growth drivers of our business remain intact."

Link to the related press feature

Siemens Healthineers 2019

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostic, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers ability to provide high-quality, efficient care to patients. In fiscal 2019, which ended on September 30, 2019, Siemens Healthineers, which has approximately 52,000 employees worldwide, generated revenue of €14.5 billion and adjusted profit of €2.5 billion.